- Home
- TIL vs DOUG Comparison
TIL vs DOUG Comparison
Compare TIL & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- DOUG
- Stock Information
- Founded
- TIL 2018
- DOUG 1911
- Country
- TIL United States
- DOUG United States
- Employees
- TIL N/A
- DOUG N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- DOUG Building operators
- Sector
- TIL Health Care
- DOUG Real Estate
- Exchange
- TIL Nasdaq
- DOUG Nasdaq
- Market Cap
- TIL 171.7M
- DOUG 147.3M
- IPO Year
- TIL 2021
- DOUG N/A
- Fundamental
- Price
- TIL $14.48
- DOUG $1.83
- Analyst Decision
- TIL Buy
- DOUG
- Analyst Count
- TIL 5
- DOUG 0
- Target Price
- TIL $114.00
- DOUG N/A
- AVG Volume (30 Days)
- TIL 178.2K
- DOUG 445.5K
- Earning Date
- TIL 05-13-2025
- DOUG 05-01-2025
- Dividend Yield
- TIL N/A
- DOUG N/A
- EPS Growth
- TIL N/A
- DOUG N/A
- EPS
- TIL N/A
- DOUG N/A
- Revenue
- TIL N/A
- DOUG $1,048,791,000.00
- Revenue This Year
- TIL N/A
- DOUG $17.61
- Revenue Next Year
- TIL N/A
- DOUG N/A
- P/E Ratio
- TIL N/A
- DOUG N/A
- Revenue Growth
- TIL N/A
- DOUG 11.36
- 52 Week Low
- TIL $9.62
- DOUG $1.00
- 52 Week High
- TIL $92.00
- DOUG $2.98
- Technical
- Relative Strength Index (RSI)
- TIL 46.45
- DOUG 60.86
- Support Level
- TIL $10.80
- DOUG $1.58
- Resistance Level
- TIL $13.52
- DOUG $1.66
- Average True Range (ATR)
- TIL 2.23
- DOUG 0.09
- MACD
- TIL -0.17
- DOUG 0.03
- Stochastic Oscillator
- TIL 27.06
- DOUG 80.77
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.